Kyverna Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 24 →Insiders5 insiders bought $2.0M in 2 open-market buys. 1 insider sold $292,776 in 1 sale, on a 10b5-1 plan.→HoldersGordonMD Global Investments 6.9%Gilead Sciences 6.7%BlackRock 5.1%→Financing →PeersClosest companies: CABA, FATE, CGEM→
From the filings
Figures
- Net income
- −$152.6Mlast 12 months
- Operating cash flow
- −$150.4Mlast 12 months
- Cash and equivalents
- $31.8Mat the last balance sheet
- Total debt
- $24.9Mat the last balance sheet
- Shares outstanding
- 61.6M shareson issue